- Home
- MD vs CDNA Comparison
MD vs CDNA Comparison
Compare MD & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MD
- CDNA
- Stock Information
- Founded
- MD 1979
- CDNA 1998
- Country
- MD United States
- CDNA United States
- Employees
- MD N/A
- CDNA N/A
- Industry
- MD Hospital/Nursing Management
- CDNA Medical Specialities
- Sector
- MD Health Care
- CDNA Health Care
- Exchange
- MD Nasdaq
- CDNA Nasdaq
- Market Cap
- MD 1.0B
- CDNA 1.1B
- IPO Year
- MD 1995
- CDNA 2014
- Fundamental
- Price
- MD $13.02
- CDNA $21.52
- Analyst Decision
- MD Buy
- CDNA Buy
- Analyst Count
- MD 7
- CDNA 8
- Target Price
- MD $15.36
- CDNA $27.17
- AVG Volume (30 Days)
- MD 787.3K
- CDNA 691.6K
- Earning Date
- MD 02-18-2025
- CDNA 02-26-2025
- Dividend Yield
- MD N/A
- CDNA N/A
- EPS Growth
- MD N/A
- CDNA N/A
- EPS
- MD N/A
- CDNA N/A
- Revenue
- MD $2,006,998,000.00
- CDNA $312,775,000.00
- Revenue This Year
- MD $3.18
- CDNA $19.85
- Revenue Next Year
- MD N/A
- CDNA $11.34
- P/E Ratio
- MD N/A
- CDNA N/A
- Revenue Growth
- MD N/A
- CDNA 5.26
- 52 Week Low
- MD $6.62
- CDNA $7.42
- 52 Week High
- MD $16.41
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- MD 32.02
- CDNA 41.67
- Support Level
- MD $13.76
- CDNA $20.35
- Resistance Level
- MD $14.69
- CDNA $21.68
- Average True Range (ATR)
- MD 0.48
- CDNA 1.13
- MACD
- MD -0.14
- CDNA -0.04
- Stochastic Oscillator
- MD 2.89
- CDNA 30.62
About MD Pediatrix Medical Group Inc.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment and generates majority of the revenue through neonatology and other pediatric subspecialties.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.